1172 related articles for article (PubMed ID: 30281843)
21. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Finazzi G; Barbui T
Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
[TBL] [Abstract][Full Text] [Related]
22. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
24. Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.
Mangaonkar AA; Hoversten KP; Gangat N
Expert Rev Hematol; 2018 Mar; 11(3):247-252. PubMed ID: 29313725
[TBL] [Abstract][Full Text] [Related]
25. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
26. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Sever M; Newberry KJ; Verstovsek S
Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
29. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
30. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
31. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
32. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
33. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Maffioli M; Mora B; Passamonti F
Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
[TBL] [Abstract][Full Text] [Related]
34. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
35. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
36. Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P; Vannucchi AM
Blood Rev; 2020 Jul; 42():100714. PubMed ID: 32546373
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
[TBL] [Abstract][Full Text] [Related]
38. It is time to change thrombosis risk assessment for PV and ET?
Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
[TBL] [Abstract][Full Text] [Related]
39. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
[TBL] [Abstract][Full Text] [Related]
40. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
